Want to see OMER full AI Analyst Report?
OMER Stock Chart & Stats
$18.22
$1.72(17.57%)
At close: 4:00 PM EDT
$18.22
$1.72(17.57%)
Day’s Range― - ―
52-Week Range$3.94 - $19.65
Previous CloseN/A
Volume2.32M
Average Volume (3M)2.01M
Market Cap
$1.35B
Enterprise Value$1.02K
Total Cash (Recent Filing)$131.95M
Total Debt (Recent Filing)$83.77M
Price to Earnings (P/E)9.6
Beta1.27
Next Earnings
Nov 11, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.91
Shares Outstanding72,388,310
10 Day Avg. Volume1,222,804
30 Day Avg. Volume2,012,446
Financial Highlights & Ratios
PEG Ratio3.32
Price to Book (P/B)-9.00
Price to Sales (P/S)0.00
P/FCF Ratio-9.39
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$33.00Price Target Upside81.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$68.00M
Bulls Say, Bears Say
Bulls Say
Rapid Yartemlia Commercial AdoptionThe first full quarter of Yartemlia sales showed rapid sequential growth and broadening account adoption, indicating meaningful physician and center engagement. Continued uptake could establish a recurring commercial revenue base and improve Omeros’ ability to fund development internally.
Reduced Convertible Debt And DilutionRetiring a substantial portion of the convertible notes lowers future interest obligations and reduces potential dilution from conversion. This strengthens capital-structure flexibility, allowing more of Yartemlia’s commercial cash generation to support operations, pipeline investment, or additional balance-sheet repair.
Diversified Pipeline And Novo Nordisk PartnershipA progressing MASP-2 franchise, additional immunology programs, and a strategic Novo Nordisk collaboration provide multiple avenues for long-term value creation beyond Yartemlia. The partnership also offers potential milestone support while external validation can help advance programs with less reliance on internal funding.
Bears Say
Negative Equity And Persistent Cash BurnNegative shareholder equity and substantial trailing cash outflows indicate that reported profitability has not yet translated into durable financial strength. This limits flexibility during commercialization and development, while continued funding needs could constrain investment or require additional financing.
European Regulatory Setback For YartemliaThe negative CHMP opinion blocks the expected European approval path unless reexamination changes the outcome, reducing the near-term geographic opportunity for Yartemlia. It also demonstrates that regulatory execution remains a material factor in converting the product’s clinical and commercial potential into broader revenue.
Limited Revenue Visibility And Rising CostsThe absence of revenue guidance makes it harder to assess how quickly launch momentum will translate into recurring company-wide revenue. At the same time, higher R&D and commercial spending will increase the cash required to support growth, potentially prolonging pressure on operating cash flow.
Omeros News
OMER FAQ
What was Omeros Corp’s price range in the past 12 months?
Omeros Corp lowest stock price was $3.94 and its highest was $19.65 in the past 12 months.
What is Omeros Corp’s market cap?
Omeros Corp’s market cap is $1.35B.
When is Omeros Corp’s upcoming earnings report date?
Omeros Corp’s upcoming earnings report date is Nov 11, 2026 which is in 60 days.
How were Omeros Corp’s earnings last quarter?
Omeros Corp released its earnings results on Aug 12, 2026. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of -$0.268 by $0.418.
Is Omeros Corp overvalued?
According to Wall Street analysts Omeros Corp’s price is currently Undervalued.
Does Omeros Corp pay dividends?
Omeros Corp does not currently pay dividends.
What is Omeros Corp’s EPS estimate?
Omeros Corp’s EPS estimate is 0.02.
How many shares outstanding does Omeros Corp have?
Omeros Corp has 72,388,310 shares outstanding.
What happened to Omeros Corp’s price movement after its last earnings report?
Omeros Corp reported an EPS of $0.15 in its last earnings report, beating expectations of -$0.268. Following the earnings report the stock price went up 26.55%.
Which hedge fund is a major shareholder of Omeros Corp?
Currently, no hedge funds are holding shares in OMER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.00 (81.12% Upside)
$33.00 (81.12% Upside)
Blogger Sentiment
Bullish
OMER Sentiment 87%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 23.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
335.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Omeros Corp
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
OMER Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a successful commercial launch for Yartemlia with very strong quarter-over-quarter sales growth (190% gross, 188% net), positive operating cash flow, meaningful balance sheet improvements via share and note repurchases, reimbursement wins (J-code and NTAP), and progress across a diversified pipeline and strategic partnership with Novo Nordisk. Offsetting items include a negative CHMP opinion in Europe, accounting volatility from derivative mark-to-market adjustments and repurchase-related losses, expected near-term increases in operating expenses, limited patient-level visibility, and one-time reimbursement items that temper recurring income visibility. On balance, the operational and commercial positives—especially the rapid U.S. uptake, cash generation, and reduced leverage/dilution—outweigh the challenges, which are largely manageable or noncash/one-time in nature.View all OMER earnings summariesOMER Stock 12 Month Forecast
Average Price Target
$33.00
▲(81.12% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Abeona Therapeutics
―
―
Foghorn Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.73% Insiders
7.87% Mutual Funds
11.25% Other Institutional Investors
63.68% Public Companies and
Individual Investors